{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:03:39Z","timestamp":1787321019474,"version":"build-2736575974"},"reference-count":100,"publisher":"Harborside Press, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>Eligibility assessment of a potential candidate for allogeneic hematopoietic cell transplantation (allo-HCT) is a complex yet vital component of pretransplant evaluation. Although no formal standardized consensus exists to guide this process, transplant centers follow institutional standard operating procedures and parameters to approve candidacy of an individual patient. Consideration for allo-HCT is dependent on a myriad of interrelated factors, including disease-related (eg, appropriate indication, disease status, prior therapies), patient-related (eg, age, functional status, frailty, comorbidities), psychosocial, and economic factors. A multidisciplinary approach is optimal for patient selection and requires the efforts of transplant coordinators, nurses, advanced practice providers, social workers, psychologists, financial specialists, and physicians. This article reviews the data and provides general guidelines that may be used in making an informed decision when evaluating a prospective candidate for allo-HCT. These recommendations are based on published data, expert commentary, reviews, and institutional practices. In the end, the eligibility assessment and decision to consider allo-HCT as the optimal choice of treatment for an individual patient are truly as much an \u201cart\u201d as it is the \u201cscience\u201d of medicine, encompassing a multidisciplinary approach to minimize harm without compromising the curative potential\u2014all essential doctrines of the Hippocratic Oath.<\/jats:p>","DOI":"10.6004\/jnccn.2020.7559","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T10:20:53Z","timestamp":1588846853000},"page":"635-643","source":"Crossref","is-referenced-by-count":29,"title":["Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.6004","volume":"18","author":[{"given":"Abraham S.","family":"Kanate","sequence":"first","affiliation":[{"name":"1Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, West Virginia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"2Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"3BMT & Cellular Therapy Program, and"},{"name":"4Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref1001","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2009.07.023","article-title":"Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation","volume":"15","author":"Baker","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2017-09-746420","article-title":"Frailty and the management of hematologic malignancies","volume":"131","author":"Abel","year":"2018","journal-title":"Blood"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00520-014-2239-7","article-title":"Psychosocial factors predicting survival after allogeneic stem cell transplant","volume":"22","author":"Pillay","year":"2014","journal-title":"Support Care Cancer"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.bbmt.2009.12.529","article-title":"Access to hematopoietic cell transplantation in the United States","volume":"16","author":"Majhail","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"ref1011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease [published online December 20, 2019]","author":"Hourigan","journal-title":"J Clin Oncol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1182\/bloodadvances.2019000790","article-title":"Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults","volume":"3","author":"Derman","year":"2019","journal-title":"Blood Adv"},{"key":"ref981","first-page":"187","article-title":"The financial requirements and time commitments of caregivers for autologous stem cell transplant recipients","volume":"4","author":"Meehan","year":"2006","journal-title":"J Support Oncol"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.30536","article-title":"Allogeneic transplantation for advanced acute myeloid leukemia: the value of complete remission","volume":"123","author":"Weisdorf","year":"2017","journal-title":"Cancer"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0277-9536(96)00101-3","article-title":"Perceived social support, family environment and psychosocial recovery in bone marrow transplant long-term survivors","volume":"44","author":"Molassiotis","year":"1997","journal-title":"Soc Sci Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/bmt.2010.94","article-title":"How we approach patient evaluation for hematopoietic stem cell transplantation","volume":"45","author":"Hamadani","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"ref01","article-title":"Current uses and outcomes of hematopoietic cell transplantation summary slides Accessed Available at https www cibmtr org","volume":"16","author":"SouzaA","year":"2019"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"key":"ref801","article-title":"Patient Eligibility for HCT Accessed November Available at https bethematchclinical org transplant indications and outcomes eligibility","year":"2019"},{"key":"ref541","first-page":"1","article-title":"Timing Impact on Outcomes Accessed November Available at https bethematchclinical org transplant indications and outcomes additional outcomes timing impact on outcomes","year":"2019"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref521","first-page":"349","article-title":"The evaluation and counseling of candidates for hematopoietic cell transplantation In eds th ed Publishing","author":"ScottB","year":"2016","journal-title":"Cell Transplantation"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.bbmt.2011.12.581","article-title":"Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure","volume":"18","author":"Freytes","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/17425255.2017.1360277","article-title":"Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review","volume":"13","author":"Myers","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbmt.2008.10.012","article-title":"Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden","volume":"15","author":"Warlick","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","article-title":"Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability","volume":"115","author":"Sarina","year":"2010","journal-title":"Blood"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref291","article-title":"Patient Eligibility for HCT Accessed November Available at https bethematchclinical org transplant indications and outcomes eligibility","year":"2019"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/bloodadvances.2019032268","article-title":"External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Shouval","year":"2019","journal-title":"Blood Adv"},{"key":"ref531","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts [published online January 21, 2020]","author":"McDonald","journal-title":"Ann Intern Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","article-title":"Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability","volume":"115","author":"Sarina","year":"2010","journal-title":"Blood"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2011-09-381699","article-title":"Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia","volume":"119","author":"Saber","year":"2012","journal-title":"Blood"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2009.07.023","article-title":"Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation","volume":"15","author":"Baker","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bbmt.2006.05.015","article-title":"Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation","volume":"12","author":"Artz","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2018018531","article-title":"Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.30536","article-title":"Allogeneic transplantation for advanced acute myeloid leukemia: the value of complete remission","volume":"123","author":"Weisdorf","year":"2017","journal-title":"Cancer"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0277-9536(96)00101-3","article-title":"Perceived social support, family environment and psychosocial recovery in bone marrow transplant long-term survivors","volume":"44","author":"Molassiotis","year":"1997","journal-title":"Soc Sci Med"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/sj.bmt.1705347","article-title":"Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation","volume":"37","author":"Andorsky","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood.2019001212","article-title":"Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR","volume":"134","author":"Dehn","year":"2019","journal-title":"Blood"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood.2019001212","article-title":"Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR","volume":"134","author":"Dehn","year":"2019","journal-title":"Blood"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/bmt.2010.94","article-title":"How we approach patient evaluation for hematopoietic stem cell transplantation","volume":"45","author":"Hamadani","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/17425255.2017.1360277","article-title":"Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review","volume":"13","author":"Myers","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2017-09-746420","article-title":"Frailty and the management of hematologic malignancies","volume":"131","author":"Abel","year":"2018","journal-title":"Blood"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2011-09-381699","article-title":"Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia","volume":"119","author":"Saber","year":"2012","journal-title":"Blood"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.2019.37.31_suppl.116","article-title":"Relationship of physical function to outcomes in autologous hematopoietic stem cell transplantation [abstract]","volume":"37","author":"Caveney","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"ref11","first-page":"349","article-title":"The evaluation and counseling of candidates for hematopoietic cell transplantation In eds th ed Publishing","author":"ScottB","year":"2016","journal-title":"Cell Transplantation"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bmt.1704062","article-title":"Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor","volume":"31","author":"Sayer","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2018018531","article-title":"Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.bbmt.2011.12.581","article-title":"Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure","volume":"18","author":"Freytes","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref501","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease [published online December 20, 2019]","author":"Hourigan","journal-title":"J Clin Oncol"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","article-title":"Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease","volume":"22","author":"Sugio","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"ref31","first-page":"1","article-title":"Timing Impact on Outcomes Accessed November Available at https bethematchclinical org transplant indications and outcomes additional outcomes timing impact on outcomes","year":"2019"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00520-014-2239-7","article-title":"Psychosocial factors predicting survival after allogeneic stem cell transplant","volume":"22","author":"Pillay","year":"2014","journal-title":"Support Care Cancer"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bbmt.2006.05.015","article-title":"Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation","volume":"12","author":"Artz","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bmt.1704062","article-title":"Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor","volume":"31","author":"Sayer","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.bbmt.2009.12.529","article-title":"Access to hematopoietic cell transplantation in the United States","volume":"16","author":"Majhail","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","article-title":"Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease","volume":"22","author":"Sugio","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref511","article-title":"Current uses and outcomes of hematopoietic cell transplantation summary slides Accessed Available at https www cibmtr org","volume":"16","author":"SouzaA","year":"2019"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.2019.37.31_suppl.116","article-title":"Relationship of physical function to outcomes in autologous hematopoietic stem cell transplantation [abstract]","volume":"37","author":"Caveney","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/bloodadvances.2019032268","article-title":"External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Shouval","year":"2019","journal-title":"Blood Adv"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/sj.bmt.1705347","article-title":"Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation","volume":"37","author":"Andorsky","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbmt.2008.10.012","article-title":"Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden","volume":"15","author":"Warlick","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1182\/bloodadvances.2019000790","article-title":"Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults","volume":"3","author":"Derman","year":"2019","journal-title":"Blood Adv"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref471","first-page":"187","article-title":"The financial requirements and time commitments of caregivers for autologous stem cell transplant recipients","volume":"4","author":"Meehan","year":"2006","journal-title":"J Support Oncol"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"key":"ref21","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts [published online January 21, 2020]","author":"McDonald","journal-title":"Ann Intern Med"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/5\/article-p635.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/18\/5\/article-p635.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T14:07:17Z","timestamp":1588946837000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/5\/article-p635.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":100,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.7559","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}